We are live on ! Find out more

United Therapeutics

UTHR

Market cap $25.7B

598.72 USD

+5.18

0.87%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

598.72

0.00

0%

1 day

0.87%

5 days

1.63%

1 month

10.49%

3 months

13.86%

6 months

4.79%

Year to date

20.53%

1 year

32.01%

5 years

209%

10 years

398.64%

About: United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Employees: 1,400

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 34.7%

Neutral 55.1%

Negative 10.2%

Zacks Investment Research

SGIOY vs. UTHR: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and United Therapeutics (UTHR).

SGIOY vs. UTHR: Which Stock Is the Better Value Option?

Zacks Investment Research

Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for

United Therapeutics Rising Ahead of Next Earnings Report

Shares of United Therapeutics Corporation (UTHR) gain 4,517% since Big Money bought big in 2004.

United Therapeutics Rising Ahead of Next Earnings Report

United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company's Investigational New Drug application to proceed with a clinical trial of Treprostinil-Iloprost SMI. The phase 1, open-label, single ascending dose study will evaluate the safety, tolerability, and pharmacokinetics of Treprostinil-Iloprost SMI in.

United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension

United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization

SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors has authorized a new share repurchase program for up to $2 billion of the company's common stock, available through October 21, 2027. “We have the balance sheet and free cash flow to fund our long-term ambitions and the confidence to act decisively when our own shares represent a compelling invest.

United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization

United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a press release that will be issued on Wednesday, November 4, 2026, at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast on Wednesday, November 4, 2026, at 9:00 a.m. Eastern Time that will be accessible at https://ir.unither.com/events-and-presentations. A rebroadcast.

United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. The company celebrated the openi.

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company's investigational new drug application to proceed with the SUMMIT clinical trial of treprostinil SMI in PH-COPD. The phase 2, 16-week, double blind SUMMIT study will evaluate the safety and tolerability of treprostinil SMI in approximately 40 patie.

United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD

Zacks Investment Research

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

Proactive Investors

Liquidia shares surge 25% as settlement ends United Therapeutics litigation

Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust disputes. The agreement removes a major source of legal uncertainty surrounding YUTREPIA, Liquidia's inhaled treprostinil treatment for pulmonary arterial hypertension, a condition involving high blood pressure in the lungs.

Liquidia shares surge 25% as settlement ends United Therapeutics litigation

See News Rankings

Price charts implemented using Lightweight Charts™